Table 1 (abstract P191). Demographic and clinical characteristics of the JIA patients by therapy. Data are medians (1st –3rd quartiles) or frequencies (%).

Age at onset, years

6.1 (3.1-10.4)

4.9 (1.9-9.7)

6.1 (3.8-9.1)

5.8 (2.7-10.1)

Age at JIA diagnosis, years

6.8 (3.3-11.9)

5.5 (2.1-10.6)

6.4 (4.1-9.2)

6.4 (3.2-11.0)

Disease duration, years

2.4 (0.9-4.8)

`2.2 (1.1-5.5)

4.1 (1.4-6.5)

2.6 (1.1-5.8)

Female

60 (75.0)

26 (72.2)

23 (71.9)

109 (73.6)

 Systemic

2 (2.5)

0

7 (21.9)

9 (6.1)

 Oligoarthritis

30 (37.5)

7 (19.4)

9 (28.1)

46 (31.1)

 Polyarthritis

27 (33.8)

23 (63.9)

13 (40.6)

63 (42.6)

 Psoriatic arthritis

1 (1.2)

0

0

1 (0.7)

 Enthesitis related arthritis

16 (20.0)

3 (8.3)

0

19 (12.8)

 Undifferentiated arthritis

4 (5.0)

3 (8.3)

3 (9.4)

10 (6.7)

Anti-Drug Antibodies*

14 (18%)

-

3 (9%)

17 (11%)

Anti-Drug Antibodies**

5 (6%)

-

2 (6%)

7 (5%)

 M0

12.6 (7–17)

15.6 (10–18.5)

15.6 (11.6–23.2)

13.5 (8.5–18.3)

 M1

4 (1.5–6.5)

5.7 (3.4–12.7)

5.5 (3–11.4)

4.5 (2–8)

 M3

2.7 (1–5.9)

2.2 (0–7.7)

2.5 (0.7–6)

2.5 (0.5–5.9)

 M6

1.5 (0–5)

1 (0–8)

2 (0.5–7.5)

1.7 (0–5.8)

 M12

0.5 (0–5)

0.5 (0–4.2)

2 (0.5–4.5)

0.5 (0–4.7)

  M1

30 (46.2)

8 (33.3)

5 (31.3)

43 (41.0)

  M3

40 (62.5)

17 (63.0)

10 (62.5)

67 (62.6)

  M6

41 (67.2)

18 (62.1)

13 (76.5)

72 (67.3)

  M12

42 (71.2)

19 (76.0)

13 (76.5)

74 (73.3)